BNRG

Price Chart

Key Facts

• Closed $1,000,000 sixth subsequent funding with Alpha Capital Anstalt on June 1, 2026.
• Issued 1,000 preferred shares with stated value $1,000 each, convertible at $1.67 per ordinary share.
• Issued warrants to purchase 598,802 ordinary shares at $14.56 per share, exercisable immediately, expiring in 5 years.
• Anti-dilution provisions lowered conversion price of all prior SPA preferred shares to $1.67.
• Post-closing: 1,895,638 ordinary shares and 3,047 preferred shares outstanding.
• Company has $1M market cap; the $1M funding is effectively 100% of market cap in new capital.
• Proceeds for general corporate purposes, working capital, and commercial TES projects.

Financial Impact

Dilution from preferred share conversion at $1.67 could add up to ~598,802 ordinary shares (warrants) plus conversion of 1,000 preferred shares (each $1,000 stated value / $1.67 = ~598.8 shares per preferred, total ~598,802 shares). Combined potential dilution: ~1.2M new shares vs 1.9M outstanding — roughly 63% dilution at current conversion prices.

Risk Factors

• Massive dilution from preferred share conversion and warrant exercise — potential 63%+ share count increase.
• Anti-dilution ratchet creates a downward spiral: each new tranche lowers conversion price, increasing dilution for existing holders.
• Reliance on a single investor (Alpha Capital Anstalt) for all funding — any disruption could halt operations.
• Proceeds used for working capital and general corporate purposes — no clear path to profitability or revenue growth disclosed.
• Registration statement to be filed for resale of underlying shares — could lead to near-term selling by Alpha.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status